Skip to main content
. Author manuscript; available in PMC: 2020 Jun 19.
Published in final edited form as: Semin Hematol. 2010 Apr;47(2):180–186. doi: 10.1053/j.seminhematol.2010.01.009

Table 1.

Studies Showing the Incidence and Characteristics of Late-Onset Neutropenia Following Rituximab-Based Therapy

Study No. of Patients Therapy Disease Type Incidence of Late-Onset Neutropenia Median Time to Neutropenia Median Duration of Neutropenia Comments
Dunleavy et al9   76
  54		 DA-EPOCH-R
DA-EPOCH		 DLBCL, ARL, MCL 8% 175 days 14 days Previously untreated patients
Nitta et al14 107
  52		 Chemotherapy + R
Chemotherapy alone		 CD20+ B-cell lymphoma 24.9% 124 days 28 days Previously untreated patients
Lai et al15 121 R-CHOP DLBCL 13.2% 129 days 69 days Previously untreated patients
Lemieux et al16   39 ACVB + R + ASCT DLBCL 15% 114 days 9 days Previously untreated patients
Cattaneo et al18     9
  50
  18		 R alone
Chemotherapy + R
R + chemotherapy + ASCT		 CD20+ B-cell lymphoma 27.3% 70 days 77 days Mix of previously untreated and treated patients
Voog et al13 N/A Rituximab-based therapy DLBCL; FL; CLL N/A 112 days 6 days Previously treated patients
Chaiwatanatorn et al19   53 Rituximab-based therapy FL; MCL; DLBCL; red cell aplasia 15% 122 days 9 days Previously treated patients
Rios-Fernandez et al17   23 Rituximab with various immunosuppressive drugs Range of autoimmune diseases 4% 191 days (1 patient) 5 days (1 patient) Patients with autoimmune diseases

Abbreviations: DA-EPOCH, dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin; R, rituximab; DLBCL, diffuse large B-cell lymphoma; ARL, AIDS-related lymphoma; MCL, mantle cell lymphoma; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; ACVB, doxorubicin, cyclophosphamide, vindesine, bleomycin; ASCT, autologous stem cell transplant; FL, follicular lymphoma; CLL, chronic lymphocytic leukemia.